Literature DB >> 15137896

HIV-1 genotyping: comparison of two commercially available assays.

Martin Stürmer1, Annemarie Berger, Wolfgang Preiser.   

Abstract

HIV-1 resistance testing has become an increasingly important feature in antiretroviral treatment and is commonly accomplished by genotyping. Currently, two different systems are being marketed and, despite being far from easy to use, have achieved a high degree of sophistication. Modifications of the standard-kit protocols may be advantageous in certain situations. Although resistance reports are issued by these systems through interpretation software based on decision rules, it nevertheless requires considerable knowledge and skills by the user to make useful clinical data out of detected resistance patterns. This review describes both systems in detail and discusses their advantages and disadvantages. A final decision on which system to use must be based on an individual's requirements. The future of this field may lie with the use of microarray systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15137896     DOI: 10.1586/14737159.4.3.281

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  3 in total

1.  Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.

Authors:  Martin Stürmer; Christoph Stephan; Peter Gute; Gaby Knecht; Markus Bickel; Hans-Reinhard Brodt; Hans W Doerr; Lutz Gürtler; Pierre Lecocq; Margriet van Houtte
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 2.  Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Authors:  Yi-Wei Tang; Chin-Yih Ou
Journal:  Emerg Microbes Infect       Date:  2012-08-22       Impact factor: 7.163

3.  Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment.

Authors:  I Michels; S Staszewski; L Gürtler; G Nisius; A Müller; L Locher; H-W Doerr; Martin Stürmer
Journal:  Eur J Med Res       Date:  2010-10-25       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.